

ALL. B2

Decreto Rettore Università di Roma “La Sapienza” n n. 2938/2019 del 03.10.2019

GIOVANNI PELLACANI
Curriculum Vitae
ai fini della pubblicazione

Place Modena
Date 11-NOV-2019

Part I – General Information

Full Name	GIOVANNI PELLACANI
Spoken Languages	Italian (mother tongue); English C2

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	1995	University of Modena and Reggio Emilia (Italy)	Medicine and Surgery 110/100 cum laude
Post-graduate studies			
PhD	2000 - 2001	1 year	Clinical and Experimental Medicine not completed because incompatible with Assistant Professor position started on 1st of November 2000
Specialty	1999	University of Modena and Reggio Emilia (Italy)	Dermatology and Venereology 50/50

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2001	2004	University of Modena and Reggio Emilia (Italy)	Assistant Professore (R.U.) in Dermatology (S.S.D. MED/35 - Malattie Cutanee e Veneree)
2004	2007	University of Modena and Reggio	Associate Professor in Dermatology

		Emilia (Italy)	(S.S.D. MED/35 - Malattie Cutanee e Veneree)
2007	2011	University of Modena and Reggio Emilia (Italy)	Full Professor (P.O.) in Technical Science Applied to Medicine (S.S.D. MED/50 - Scienze tecniche mediche applicate)
2011	today	University of Modena and Reggio Emilia (Italy)	Full Professor in Dermatology (S.S.D. MED/35 - Malattie Cutanee e Veneree)
2015	today	University of Modena and Reggio Emilia (Italy)	Dean of the Faculty /School of Medicine and Surgery (pro-tempore 2015-2018 and 2018-2021)

IIIB – Other Appointments

Start	End	Institution	Position
2012	2019	University of Modena and Reggio Emilia (Italy)	Director of the School of Dermatology and Venereology (Residency program)
2012	today	Azienda Ospedaliero Universitaria di Modena (Italy)	Director of the Dermatology Clinic (Unità Operativa Complessa - U.O.C.) of Dermatology
2015	today	University of Modena and Reggio Emilia (Italy)	Dean (Presidente) of the Faculty / School of Medicine and Surgery (pro-tempore 2015-2018 and 2018-2021)
2015	today	Conferenza Permanente Presidenti Corso di Laurea in Medicina e Chirurgia	Member
2017	2019	Provincia di Modena	Member of the CTSS (Conferenza Territoriale Socio Sanitaria)
2018	today	Regione Emilia Romagna	President of the "Osservatorio Regionale Scuole di Specialità"

Part IV – Teaching experience

Year	Institution	Lecture/Course
2001-today	University of Modena and Reggio Emilia	CdL Medicina e Chirurgia
2005-2016	University of Modena and Reggio Emilia	CdL Infermieristica
2003-today	University of Modena and Reggio Emilia	Scuola di Specialità Dermatologia
2003-today	University of Modena and Reggio Emilia	Scuola di Specialità Chirurgia Plastica
2003-2016	University of Modena and Reggio Emilia	Scuola di Specialità Tossicologia
2003-2016	University of Modena and Reggio Emilia	Scuola di Specialità Pediatria
2007	University of Brisbane (Australia)	Visiting Professor School of Dermatology

Part V - Society memberships, Awards and Honors

Year	Title
	SCIENTIFIC SOCIETIES - BOARD MEMBER:
2016-2023	International League of Dermatological Societies (ILDS) - Board Member
from 2008	European Association of Dermato-Oncology (EADO) - Board Member
from 2011	International Dermoscopy Society (IDS) - Board member
from 2010	International Confocal Group (ICG) - Board Member
2013-2016	Società Italiana di Dermatologia e Malattie sessualmente Trasmesse (SIDeMaST) - Board Member
2006-2011	Associazione Italiana Diagnostica Non Invasiva (AIDNID) - Board Member
	SCIENTIFIC SOCIETIES - ORDINARY MEMBER:
from 1996	Società Italiana di Dermatologia e Malattie sessualmente Trasmesse (SIDeMaST) - Member
from 1996	Associazione Italiana Diagnostica Non Invasiva (AIDNID) - member
from 2006	European Academy of Dermatology and Venereology (EADV) - member
from 2008	American Academy of Dermatology (AAD) - member
from 2013	European Dermatology Forum (EDF) - member
from 2016	American Association of Dermatology (ADA) - member
	JOURNAL EDITORIAL BOARD
from 2017	Journal of the American Academy of Dermatology (J Am Acad Dermatol) I.F.
from 2015	Journal of the European Academy of Dermatology and Venereology (J Eu Acad Dermatol Venereol) I.F.
	PRESIDENT OF CONGRESSES
2019	President of the 24th World Congress of Dermatology - Milan June 2019 Participants: 16.447; Total budget 21.618.189,38 €
2018	President of the 1st World Congress of Confocal Microscopy - Rome October 2018 Participants 223; Total budget 107.439,91 €
2017	Co-president of the Annual Congress of AIDNID - Modena February 2017 Participants 406; Total budget 122.514,70 €
2014	Co-president of the 89th Congress of SIDeMaST - Parma May 2014 Participants 990; Total budget 1.285.804,21 €
	PATENT
2017	EU PATENT OFFICE: A computer implemented method, a system and computer program products to characterize a skin lesion. REF. 17-8459 EP of the 17-JAN-2017

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

A. COMPETITIVE ISTITUTIONAL NO PROFIT GRANTS:

Year	Title	Program	Grant value
2016-2020	High technology skin cancer diagnosis implemented in a research hospital network in emilia-romagna for early accurate skin cancer detection in a cost-saving model - Project n. NET-2011-02347213	Clinical health care research - Network Project, Ministry of Health (Ricerca Finalizzata)	Project PI Total: € 1.056.952,48 Local: € 417.676,48
2016-2019	Aggressiveness and response to therapy of melanoma subtypes selected by reflectance confocal microscopy - n 16890/2015	AIRC (Associazione Italiana per la Ricerca sul Cancro) Investigator Grant - IG 2015	Project PI Total/Local € 302.000,00
2014-2017	Integrated imaging/molecular/genetic technologies for characterization of melanoma subtypes, for diagnosis improvement, biological aggressiveness estimation and predictive factors identification - Prot. N. 2012JJX494	Project of National Relevance in Italy (PRIN), Ministry of University, Instruction and Research (MIUR)	Project PI Total: € 423.000 ,00 Local: € 132.857,00
2013-2016	DIAGNOPTICS: Diagnosis of skin cancer using optics - Grant agreement no: 621066.	European Project CIP: Competitive and Innovation Framework Programme 2007-2013 (EU project)	PI local Total: € 2.372.000,00 Local: € 362.260,00
2013-2016	ADVANCE: Automatic Detection of VAscular Networks for Cancer Evaluation - Grant agreement no: 621066	European Project CIP: Competitive and Innovation Framework Programme 2007-2013 (EU project)	PI local Total: € 2.282.143,00 Local: € 341.207,00
2009-2012	SKINSPECTION: : multimodal skin inspection with hybrid acoustic and optical spectroscopic imaging	European Project CIP: FP7 Program - European Project VII Frameeork Program for the Researc and Technological Development of the European Union (EU project)	I and PI local (from 2011) Total: € 4.097.585,00 Local: € 402.200,00
2006-2013	From dysplastic nevus to melanoma: a functional proteomic approach for the identification of potential biomarkers - Project nr. 527/B/3A/4	ISS/NIH Italy-USA program in oncoproteomics	I
2007-2013	The development of dermatology as integrated line of medical higher education studies and of a network universities in the field - n. 56/1.2/S/31081	POSDRU - The European Social Fund/The Operational Programme Human Resources	I (role: long-term Expert)
2004-2006	Telediagnosis and automated diagnosis for the early detection of melanoma Tele-diagnosi e diagnosi automatica per la individuazione precoce del melanoma - prot. n. 2004063811	Project of National Relevance in Italy (PRIN), Ministry of University, Instruction and Research (MIUR)	I

2002-2004	Toxic and essential elements (Selenium, Cadmium, Zinc, Cupron) in determining neoplastic diseases - prot n. 2002063519	Project of National Relevance in Italy (PRIN), Ministry of University, Instruction and Research (MIUR)	I
2001-2003	NEW INDIVIDUAL RISK FACTORS FOR MELANOMA IN THE ITALIAN POPULATION: a study of phenotypic and genotypic aspects by epidemiologic, molecular, bioengineering and statistical methods - prot n. 2001068929	Project of National Relevance in Italy (PRIN), Ministry of University, Instruction and Research (MIUR)	I
1999-2001	Digital applications in the melanoma diagnosis - prot n. 9906308882	Project of National Relevance in Italy (PRIN), Ministry of University, Instruction and Research (MIUR)	I
	TOTAL		Total: € 9.808.680,48 Local: € 1.595.940,48

B. NO PROFIT (INVESTIGATOR INITIATED) SPONSORED STUDIES:

Year	Title	Sponsor	Grant value
2016	Minerva Studio clinico per indagare gli effetti del trattamento sistemico con i prodotti GOLD COLLAGEN® sulle proprietà di epidermide/derma e cuoio capelluto mediante microscopia confocale e dermatoscopia digitale”.	Minerva	€ 97.000
2017	Heliocare: Il ruolo della fotoprotezione TOPICA ED ORALE nel prevenire/ridurre il rischio di danno attinico in una popolazione “a rischio”	IFC Cantabria	€ 125.000
	SUNSIMED: “The role of photoprotection in the widespread prevention of sundamage alterations - Ruolo della fotoprotezione nella prevenzione integrale delle alterazioni da fotodanno”.	Pierre Fabre	€ 124.000
2018	ImmunoMela: “Biomarkers of response to immunotherapy in patients with metastatic melanoma stage IV” [Biomarcatori di risposta all’immunoterapia nei pazienti con melanoma metastatico IV stadio].	Fondazione CRM di Modena	€ 130.000
2019	Studio sperimentale senza farmaco per la valutazione di un integratore alimentare a base di probiotici e di un trattamento topico/dermoc cosmetico in soggetti con cute a tendenza acneica”.	Bionike	€ 20.000
	TOTAL		€ 496.000,00

C. PROFIT (SPONSOR INITIATED) STUDIES AND CLINICAL TRIALS:

Year	Title	Sponsor	Grant value
2013	D pigment “EFFICACIA E TOLLERANZA DEL D-PIGMENT VERSUS IDRATANTE SULLE LENTIGO DELLE MANI CON E SENZA TRATTAMENTO LASER”	Pierre-Fabre	€ 72.000,00
2014	CAIN457A2317 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to	Novartis	€ 27.200,00

	demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab ...		
2014	MK-3222 Protocol 011: A 52-Week , Phase 3, active comparator and placebo-controlled study to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222 in subjects with moderate-to severe chronic plaque psoriasis	Merck	€ 164.248,00
2015	CAIN457AIT01 (SUPREME) A 24-week, multicenter, prospective, open-label study to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety profile of secukinumab 300 mg in Cw6-negative and Cw6-positive patients with moderate to severe chronic plaque-type psoriasis (SUPREME)	Novartis	€ 40.000,00
2016	LP0084-1194 - Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up	LeoPharma	€ 46.560,00
2017	Studio dell'efficacia di una crema emolliente in modelli in vitro 3D-Tape stripping e su soggetti affetti da dermatite atopica	DREX-Pharma	€ 30.766,00
2018	REROS REROS/001/17 "Sicurezza ed efficacia di Rifaximina, compresse a rilascio ritardato da 400 mg, in pazienti con rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio. Uno studio clinico multicentrico, in doppio-cieco, randomizzato e controllato verso placebo", EudraCT 2017-003722-33.	Alfasigma	€ 40.000,00
2018	ABBVIE M18-891 "Studio Clinico di Fase 3, randomizzato, in Doppio Cieco, Controllato verso Placebo per Valutare Upadacitinib in Soggetto Adolescenti e Adulti Affetti da Dermatite Atopica di Grado da Moderato a Grave (A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis)", EudraCT: 2018-001383-28	Abbvie	€ 46.282,00
2018	PFIZER B7451014 "Studio di fase 3, randomizzato e di ritiro, in doppio cieco, controllato verso placebo, multicentrico per valutare l'efficacia e la sicurezza di PF-04965842 in soggetti di 12 o più anni di età, affetti da dermatite atopica da moderata a grave, con l'opzione di un trattamento di salvataggio per i soggetti che presentano una riacutizzazione, Numero EudraCT: 2018-000501-23.	Pfizer	€ 30.766,00
2018	CANOVA CAIN457AIT07 (CANOVA) "Descrizione della risposta al trattamento con farmaci biologici per la psoriasi a placche in Italia: uno studio osservazionale longitudinale della reale pratica	Novartis	€ 33.000,00

	clinica”.		
2018	DIMESKIN M-41008-42 "STUDIO CLINICO IN APERTO PER VALUTARE L'EFFICACIA E LA TOLLERABILITÀ A LUNGO TERMINE DEL TRATTAMENTO CON DIMETILFUMARATO (DMF) IN ADULTI AFFETTI DA PSORIASI CRONICA A PLACCHE	Almirall	€ 20.000,00
2018	COMBI A PLUS CDRB436F2410 “COMBI-APlus: Studio in aperto, di Fase IIIb con dabrafenib in COMBINazione con trametinib nel trattamento Adiuvante del melanoma in stadio III positivo per la mutazione BRAF V600 dopo resezione completa, per valutare l’impatto sugli esiti correlati alla piressia di un algoritmo per la gestione degli eventi avversi adattato alla piressia (Plus)”,	Novartis	€ 98.350,00
2018	ORTICARIA A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines”	Novartis	€ 17.000,00
2018	PFIZER B7451015 “Studio di estensione di fase 3, multicentrico, a lungo termine per valutare l’efficacia e la sicurezza di PF-04965842, con o senza farmaci topici, somministrato in soggetti di 12 o più anni di età, affetti da dermatite atopica da moderata a grave”,	Pfizer	€ 17.764,00
2018	OBSERVATIONAL, PROSPECTIVE, COHORT STUDY TO CONFIRM THE LONG TERM SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETROVIRAL (RV) VECTOR CARRYING LAMB3 cDNA FOR RESTORATION OF EPIDERMIS IN PATIENTS WITH JUNCTIONAL EPIDERMOLYSIS BULLOSA	Holostem	€ 17.500,00
2019	PFIZER B7451029 STUDIO DI FASE III RANDOMIZZATO, MULTICENTRICO, IN DOPPIO CIECO, A DOPPIO MASCHERAMENTO, CONTROLLATO CON PLACEBO, A GRUPPI PARALLELI, VOLTO A VALUTARE L'EFFICACIA E LA SICUREZZA DI PF 04965842 E DUPILUMAB RISPETTO AL PLACEBO IN SOGGETTI ADULTI AFFETTI DA DERMATITE ATOPICA DA MODERATA A GRAVE TRATTATI CON TERAPIA TOPICA DI BASE	Pfizer	€ 13.000,00
2019	ACNE-SCAR IBSA CD-14014-1 “Indagine pilota in aperto di efficacia e sicurezza sugli effetti dei dispositivi medici ClearSkin™ e PROFHILO® nel	IBSA	€ 10.000,00

	trattamento delle cicatrici da acne facciale (Open-label, pilot efficacy and safety investigation on the effects of ClearSkin™ Module and PROFHILO® in the treatment of Facial Acne Scars)”.		
2019	RUGHE-IBSA CD14014-2 “Indagine pilota in aperto di efficacia e sicurezza sugli effetti dei dispositivi medici ClearLift™ e PROFHILO® nel trattamento delle rughe facciali (Open-label, pilot efficacy and safety investigation on the effects of ClearLift™ Module and PROFHILO® in the treatment of Facial Skin Wrinkles).	IBSA	€ 20.000,00
2019	STRIAE-IBSA CD 13001-1 “Indagine first in human in aperto, di sicurezza e di efficacia di un nuovo complesso ibrido iniettabile, una siringa pre-riempita con acido ialuronico e condroitina biotecnologica nel trattamento intradermico delle striae distensae alba””	IBSA	€ 27.000,00
2019	AIN457M2301 (ISRCTN12345678, NCT12345678, UTRN U1234- 1234-1234) “Studio multicentrico, randomizzato, in doppio cieco, per valutare l’efficacia a breve termine (16 settimane) e a lungo termine (fino a 1 anno), la sicurezza e la tollerabilità di 2 schemi di dosaggio di secukinumab s.c. in pazienti adulti con idrosadenite suppurativa di grado da moderato a severo (SUNSHINE) [Studio per valutare la terapia con secukinumab in pazienti adulti con idrosadenite suppurativa di grado da moderato a severo]”	Novartis	€ 24.570,00
2019	PSO LILLY IIF-MC-B007 “Studio sugli esiti sanitari associati alla psoriasi (PSoHO): studio osservazionale internazionale degli esiti sanitari a 3 anni del trattamento biologico della psoriasi a placche da moderata a grave [Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis]”.	Lilly	€ 34.200,00
2019	ReGI/18/Rcr/Der/001 “Indagine clinica monocentrica, in aperto, non controllata, sulla prestazione e sicurezza di Relizema cream nella dermatite atopica e nella dermatite da contatto, nel soggetto adulto (Monocenter, open label, uncontrolled clinical investigation on the performance and safety of Relizema cream in the atopic dermatitis and contact dermatitis in the adult)	Menarini	€ 20.000,00
	TOTAL		€ 850.206,00

TOTAL FUNDING GENERATED FOR THE INSTITUTIONS (UNIMORE / AOU MODENA) = € 2.942.146,48

Part VII – Research Activities

Keywords	Brief Description
Dermoscopy in vivo reflectance confocal microscopy optical coherence tomography ex vivo fluorescence confocal microscopy	<p>Research mainly in the field of dermatology, non invasive diagnosis, cutaneous physiopathology, skin bio-engineering for the evaluation of inflammatory diseases, since 1995.</p> <ol style="list-style-type: none"> 1. Melanoma and pigmented skin lesion diagnosis, early identification, pattern characterization, by means of dermoscopy, also in combination with system for image analysis and automated diagnosis 2. Melanoma and non-melanoma skin cancer in vivo reflectance confocal microscopy for the study of cytological and architectural aspects of the skin and of skin lesions, in correlation with dermoscopy and histopathology are the present and most relevant fields of research. Since 2003, his main research interest is in the field of in vivo confocal microscopy for the diagnosis and characterization mostly of skin cancer. 3. Laboratory research: melanoma features have been described and validated. Histopathology correlation, immuno-histochemistry for identification of bio-markers and genetics for characterization of familial syndromes and somatic mutations related with different tumor aspects and aggressiveness. 4. Application of new technologies integrated with other imaging modalities, including optical coherence tomography and speckle variance tomography for skin cancer and inflammatory skin diseases 5. Skin aging, dermo-cosmetology, pathophysiology of the skin. Study of the skin barrier and allergic/irritant dermatitis with the use of non-invasive technologies. 6. Drug efficacy, quality of life and metabolic syndrome in patients with psoriasis and other inflammatory skin diseases, with a focus on acne pathogenesis and treatment. 7. Ex-vivo fluorescence confocal microscopy for rapid histopathology in basal cell carcinoma, inflammatory skin diseases and other visceral cancers (including prostate cancer)
melanoma	
basal cell carcinoma	
actinic keratosis	
psoriasis	
Aging	
Inflammatory skin diseases	
cosmetology	
genetic markers	

LIST OF RELEVANT PUBLICATIONS (Attachment n.B1)

Part VIII – Summary of Scientific Achievements

Data from Scopus and ISI Web of Science - Certified by the Bibliometric Office of the University of Modena and Reggio Emilia (Attachment n.B2)

Product type	Number	Data Base	Start	End
Papers [international]	439 [317 Articles; 6 Editorial; 69 Letters; 42 Reviews]. <u>1st Author</u> in 33 Articles; 4 Letters. <u>Last Author</u> in 85 Articles; 20 Letters; 16 Reviewss. <u>Corresponding</u> in 31 Articles; 5 Letters; 3 Reviews 164 papers (54.5%) in the last 10 years from International collaborations	Scopus/ WoS	1996	2019
Papers [IF>6]	29 <u>1st/last/Corr.</u> in 6 papers	Scopus/ WoS	1996	2019
Papers [national]	23 [21 Articles (18 Ita; 2 French; 1 Brasil); 2 Letters] <u>1st Author</u> in 1 Article <u>Last Authors</u> in 3 Articles <u>Corresponding</u> in 2 Articles	Scopus/ WoS	1996	2019
Books [scientific]	1 Book as Editor + 26 Chapters in books. <u>1st Author</u> in 2 Chapters <u>Last Authors</u> in 16 Chapters <u>Corresponding</u> in 5 Chapters	Scopus/ WoS	1996	2019
Conference paper	5 (International conferences)	Scopus/ WoS	1996	2019
TOTAL	494			

Total Impact factor	1390,59
Impact Factor (last 10 years)	1214.05
Average IF per Product (calculated on the 440 ISI products)	3,16
Total Citations	9069
Average Citations per Product	18,6
Hirsch (H) index	47
Normalized H index*	1,96

*H index divided by the academic seniority

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any)

N	Authors	Title	Reference data	Journal IF* ISI	citations
1	Pellacani G. , Cesinaro A.M., Seidenari S.	Reflectance-mode confocal microscopy of pigmented skin lesions-improvement in melanoma diagnostic specificity	Journal of the American Academy of Dermatology. 2005; 53(6):979-985	2,402	182

2	Pellacani G. , Guitera P., Longo C., Avramidis M., Seidenari S., Menzies S.	The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions	Journal of Investigative Dermatology. 2007; 127(12):2759-2765	4,829	291
3	Guitera P., Menzies S.W., Longo C., Cesinaro A.M., Scolyer R.A., Pellacani G.	In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: Analysis of 710 consecutive clinically equivocal cases	Journal of Investigative Dermatology. 2012; 132(10):2386-2394	6,193	185
4	Longo C., Casari A., Beretti F., Cesinaro A.M., Pellacani G.	Skin aging: In vivo microscopic assessment of epidermal and dermal changes by means of confocal microscopy	Journal of the American Academy of Dermatology. 2013; 68(3):e73-e82	5,004	95
5	Longo C., Farnetani F., Ciardo S., Cesinaro A.M., Moscarella E., Ponti G., Zalaudek I., Argenziano G., Pellacani G.	Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases	British Journal of Dermatology. 2013; 169(1):58-67	4,1	80
6	Rao B.K., Mateus R., Wassef C., Pellacani G.	In vivo confocal microscopy in clinical practice: Comparison of bedside diagnostic accuracy of a trained physician and distant diagnosis of an expert reader	Journal of the American Academy of Dermatology. 2014; 27(3):460-471	5,004	30
7	Pellacani G. , Pepe P., Casari A., Longo C.	Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: A longitudinal prospective study	British Journal of Dermatology. 2014; 171(5):1044-1051	4,275	99
8	Farnetani F., Scope A., Braun R.P., Gonzalez S., Guitera P., Malvey J., Manfredini M., Marghoob A.A., Moscarella E., Oliviero M., Puig S., Rabinovitz H.S., Stanganelli I., Longo C., Malagoli C., Vinceti M., Pellacani G.	Skin cancer diagnosis with Reflectance confocal microscopy: Reproducibility of feature recognition and accuracy of diagnosis	JAMA Dermatology. 2015; 151(19):1075-1080	5,097	61
9	Ferrari B., Pupelli G., Farnetani F., De Carvalho N.T., Longo C., Reggiani C., Argenziano G., Pellacani G.	Dermoscopic difficult lesions: An objective evaluation of reflectance confocal microscopy impact for accurate diagnosis	Journal of the European Academy of Dermatology and Venereology. 2015; 29(6):1135-1140	3,029	27
10	De Carvalho N., Farnetani F., Ciardo S., Ruini C., Witkowski A.M., Longo C., Argenziano G., Pellacani G.	Reflectance confocal microscopy correlates of dermoscopic patterns of facial lesions help to discriminate lentigo maligna from pigmented nonmelanocytic	British Journal of Dermatology. 2015; 173(1):128-133	4,317	36

		macules			
11	Scope A., Selinger L., Oliviero M., Farnetani F., Moscarella E., Longo C., Rabinovitz H.S., Pellacani G.	Precise longitudinal tracking of microscopic structures in melanocytic nevi using reflectance confocal microscopy a feasibility study	JAMA Dermatology. 2016; 152(3):299-304	5,817	4
12	Manfredini M., Greco M., Farnetani F., Ciardo S., De Carvalho N., Mandel V.D., Starace M., Pellacani G.	Acne: morphologic and vascular study of lesions and surrounding skin by means of optical coherence tomography	Journal of the European Academy of Dermatology and Venereology. 2017; 31(9):1541-1546	4,287	14
13	Mandel V.D., Cinotti E., Benati E., Labeille B., Ciardo S., Vaschieri C., Cambazard F., Perrot J.L., Pellacani G.	Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding subclinical lesions	Journal of the European Academy of Dermatology and Venereology. 2018; 32(9): 1562-1569	5,113	3
14	Pellacani G. , De Carvalho N., Ciardo S., Ferrari B., Cesinaro A.M., Farnetani F., Bassoli S., Guitera P., Star P., Rawson R., Rossi E., Magnoni C., Gualdi G., Longo C., Scope A.	The smart approach: feasibility of lentigo maligna superficial margin assessment with hand-held reflectance confocal microscopy technology	Journal of the European Academy of Dermatology and Venereology. 2018; 32(10):1687-1694	5,113	3
15	Manfredini M., Bettoli V., Sacripanti G., Farnetani F., Bigi L., Puviani M., Corazza M., Pellacani G.	The evolution of healthy skin to acne lesions: a longitudinal, in vivo evaluation with reflectance confocal microscopy and optical coherence tomography	Journal of the European Academy of Dermatology and Venereology. 2019; 139(2):464-466	5,113	0
16	Pellacani G. , Scope A., Gonzalez S., Guitera P., Farnetani F., Malveyh J., Witkowski A., De Carvalho N., Lupi O., Longo C.	Reflectance confocal microscopy made easy: The 4 must-know key features for the diagnosis of melanoma and nonmelanoma skin cancers	Journal of the American Academy of Dermatology. 2019; 81(2):520-526	7,102	0

* IF in the year of the publication

in faith



 Giovanni Pellacani